Ewa Łucja Gregoraszczuk

Expression of ghrelin receptor, GHSR-1a, and its functional role in the porcine ovarian follicles

Recently, we reported stimulatory effect of ghrelin alone and in combination with growth hormone (GH) on estradiol secretion, aromatase activity in parallel with inhibitory effect on cell apoptosis. The aim of this study was to analyze the expression of the functional ghrelin receptor (GHS-R type 1a) and the effect of GH on GHSR-1a expression in cultured whole porcine follicles. Using RT-PCR and Western Blots, we demonstrated the presence of GHSR-1a in prepubertal pig ovary and found no influence of GH on either GHSR-1a protein levels or mRNA expression. Additionally, to show if, noted previously by us action of ghrelin on ovarian follicular function is dependent of its binding to GHSR-1a, we used an antagonist of the ghrelin receptor, (D-Lys-3)-GHRP-6. In cultures treated together ghrelin and (D-Lys-3)-GHRP-6, estradiol secretion, aromatase activity and cell proliferation returned to control levels. Inhibitory action on caspase-3 activity was not reversed by a selective antagonist of GHSR-1a. In conclusion, results of the present data clearly showed: (1) the presence of GHSR-1a in prepubertal pig ovary and found no influence of GH on GHSR-1a protein levels and mRNA expression, and (2) ghrelin effect on estradiol secretion, aromatase activity and cell proliferation dependent of its binding to GHSR-1a, while the effect on cellular apoptosis was independent of its binding to GHSR-1a.

Effects of single and repeated in vitro exposure of three forms of parabens, methyl-, butyl- and propylparabens on the proliferation and estradiol secretion in MCF-7 and MCF-10A cells

BACKGROUND Here, we analyzed the dose- (0.2, 2, 20, 200 nM or 2 μM) and time- (48, 96, 144 and 196 h) dependent activity of a single or repeated exposure of methyl-, butyl- and propylparaben on the proliferation of MCF-7 human breast cancer cells and MCF-10A human breast epithelial cells. Additionally, the effect on estradiol secretion, gene and protein expression of aromatase (CYP19A1) was investigated. METHODS Cell proliferation was determined by AlamarBlue assay, and estradiol secretion by ELISA kits. Gene and protein expression of CYP19A1 was measurement using real time PCR and western blot, respectively. RESULTS Stimulatory effect of a single exposure of all doses of tested parabens and time dependent effect of repeated exposure to methylparaben, propylparaben and butylparaben, the same as that of 17β-estradiol, on proliferation of MCF-7 cells was observed. Only at low doses methyl- and butylparabens increased MCF-10A cells proliferation after single exposure, but no effect of repeated exposure was noted. Exposure at low doses of all of the parabens significantly increased 17β-estradiol (E2) secretion in MCF-7 cells but had the opposite effect on MCF-10A cells. It was correlated with gene and protein expression of CYP19A1 in MCF-7 and MCF-10 cells. CONCLUSIONS In summary, present study indicates a different mechanism of proliferative action of parabens in investigated cell lines. In MCF-7 breast cancer cell line it is probably due to stimulatory action on estradiol secretion and aromatase activity. In MCF-10A by an unknown mechanism, independent on stimulatory action on estradiol section, which requires further investigation.

Actions of methyl-, propyl- and butylparaben on estrogen receptor-α and -β and the progesterone receptor in MCF-7 cancer cells and non-cancerous MCF-10A cells.

Numerous studies have shown that widely used parabens possess estrogenic properties. In the present study, we examined the effects of methyl-, propyl- and butylparaben on the mRNA and protein expression of estrogen receptor (ER)-α (ESR1) and -β (ESR2) and the progesterone receptor (PGR). Human MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells were exposed to parabens at a concentration of 20nM; 17β-estradiol at a concentration of 10nM, was used as a positive control. Both propyl- and butylparaben stimulated PGR mRNA expression in MCF-7 cells, whereas methyl- and propylparaben PGR protein expression. In MCF-10A cells, butyl- and propylparaben increased only PGR mRNA expression. All parabens increased ESR1 gene and protein expression in MCF-7 and with the exception of butylparaben in MCF-10A cells. All parabens significantly increased ESR2 mRNA and protein expression in MCF-7 cells, but in MCF-10A cells only ESR2 protein expression. In summary, by virtue of their stimulatory action on the expression of ESR1, ESR2 and PGR in cancer cells, parabens can be viewed as potential contributors to breast cancer progression. Extension, the actions of these parabens on the expression of ERs and PGR in non-cancerous cells point to possible actions on breast cancer initiation.

Action of methyl-, propyl- and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells

In the present study, we examined cAMP levels and activation of the MAPK/ERK1/2 and PI3K/Akt signaling pathways in response to the actions of parabens on GPR30 in MCF-7 and MCF-10A cells. Cells were exposed to methyl-, propyl- or butylparaben at a concentration of 20nM; 17-β-estradiol (10nM) was used as a positive control. 17β-estradiol and all tested parabens increased GPR30 gene and protein expression in MCF-7 and MCF-10A cells. No parabens affected cAMP levels in either cell line, with the exception of propylparaben in MCF-10A cells. 17β-estradiol, propylparaben, and butylparaben increased phosphorylation of ERK1/2 in MCF-7 cells, whereas 17β-estradiol, methyl- and butylparaben, but not propylparaben, increased phosphorylation of ERK1/2 in MCF-10A cells. Akt activation was noted only in MCF-7 cells and only with propylparaben treatment. Collectively, the data presented here point to a nongenomic mechanism of action of parabens in activation GPR30 in both cancer and non-cancer breast cell lines through βγ dimer-mediated activation of the ERK1/2 pathway, but not the cAMP/PKA pathway. Moreover, among investigated parabens, propylparaben appears to inhibit apoptosis in cancer cells through activation of Akt kinases, confirming conclusions suggested by our previously published data. Nevertheless, continuing research on the carcinogenic action of parabens is warranted.

Differential effect of methyl-, butyl- and propylparaben and 17β-estradiol on selected cell cycle and apoptosis gene and protein expression in MCF-7 breast cancer cells and MCF-10A non-malignant cells.

Parabens are alkyl esters of p‐hydroxybenzoic acid used widely as antimicrobial preservatives in consumer products, including pharmaceuticals, foods and cosmetics. We showed previously that methyl‐, butyl‐ and propylparaben parabens, even at low doses, stimulate the proliferation of MCF‐7 breast cancer cells and non‐transformed MCF‐10A breast epithelial cells. The present study was undertaken to determine whether this represents a direct effect on cell cycle and apoptotic gene expression. MCF‐7 and MCF‐10A cells were exposed to methyl, butyl‐ and propylparaben (20 nm) or 17β‐estradiol (10 nm). Cell cycle and apoptotic gene expression were evaluated by real‐time polymerase chain reaction and protein expression by Western blot. 17β‐estradiol upregulated G1/S phase genes and downregulated cell cycle progression inhibitors in both MCF‐7 and MCF‐10A. Upregulation of Bcl‐xL and downregulation of caspase 9 was observed in MCF‐7, while upregulation of Bcl‐xL, BCL2L2 and caspase 9 was noted in MCF‐10A. Cyclins in MCF‐7 cells were not affected by any of the parabens. Methyl‐ and butylparaben had no effect on the expression of selected apoptotic genes in MCF‐7. In MCF‐10A, all parabens tested increased the expression of G1/S phase genes, and downregulated cell cycle inhibitors. Methylparaben increased pro‐survival gene. Butylparaben increased BCL2L1 gene, as did 17β‐estradiol, while propylparaben upregulated both the extrinsic and intrinsic apoptotic pathways. There are differences in cell cycle and apoptosis gene expression between parabens and 17β‐estradiol in MCF‐7 cells. In MCF‐10A cells, most of the genes activated by parabens were comparable to those activated by 17β‐estradiol. Copyright

Halowax 1051 affects steroidogenesis, 17β-hydroxysteroid dehydrogenase (17β-HSD) and cytochrome P450arom (CYP19) activity, and protein expression in porcine ovarian follicles.

We evaluated the effect of Halowax 1051 on ovarian follicular testosterone (T) and estradiol (E2) secretion determined by EIA and on the expression of 17β-HSD and CYP19 analyzed by Western blot. 17β-HSD and CYP19 activity were determined indirectly by measuring the conversion of androstenedione (A4) to T and T to E2, respectively. Additionally, CYP19 activity by dibenzylfluorescein assay. Follicles were exposed to 1-1000pg/ml of Halowax 1051 for 24, 48 or 72h. It was found that Halowax 1051, in all doses used, increased basal T secretion concomitant with a decrease in basal E2 secretion. Inhibitory action on 17β-HSD and stimulatory action on CYP19 (activity and protein expression) under the influence of 1pg/ml, and opposite effect under the influence of 10-1000pg/ml was noted. In conclusion, we suggest non-linear dose-response effect of Halowax 1051 on steroidogenesis and steroidogenic enzymes activity and protein expression.

Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line

Concentration- and time-dependent effects of two antiepileptic drugs (AEDs), levetiracetam (LEV) and valproic acid (VPA), on proliferation, cytotoxicity and expression of cell cycle regulatory genes were investigated in a human ovarian cancer cell line, OVCAR-3. Cells were cultured with VPA or LEV, at concentrations between 100 μM and 10 mM. Cell proliferation was determined by alamarBlue and BrdU incorporation assays; cytotoxic effects by tetrazolium hydroxide (XTT), acid phosphatase (AP) and lactate dehydrogenase (LDH) assays. Expression of cell cycle regulatory genes was determined by real-time PCR. Exposure to VPA caused a concentration- and time-dependent decrease in cell proliferation (alamarBlue and BrdU incorporation assays), cytotoxic effects above 2.5 mM (XTT and AP assays) and modulated expression of genes primarily responsible for cell cycle arrest in G(1) phase. Cell proliferation was unaffected by exposure to LEV for 24 h and 120 h (alamarBlue assay), but increased when exposed to LEV for 72 h and 168 h, at concentrations from 250 μM to 1 mM. The BrdU incorporation assay showed no effect of LEV on cell proliferation. LEV was cytotoxic at higher concentrations (AP assay), but modulation in expression of cell cycle regulatory genes was not observed. Changes in LDH release were not observed with either AED. In summary, VPA apparently decreased cell proliferation by down-regulating genes responsible for transition from G(1) to S phase and up-regulating genes responsible for G(1) phase arrest, which suggest its potential as an anticancer drug. LEV does not exhibit such action.

Combinatory effects of PBDEs and 17β-estradiol on MCF-7 cell proliferation and apoptosis.

In the present work, we analyzed whether polybrominated diphenyl ethers (PBDEs) (47, 99, 100 and 209) interfere with the effect of 17β-estradiol on the proliferation and apoptosis of the MCF-7 cell line. MCF-7 cells were cultured in DMEM without phenol red; upplemented with 5% charcoal-treated fetal bovine serum for 3 days with 10 nM 17β-estradiol; with 0.1 μM, 0.5 μM or 1 μM of the tested PBDE congeners; or with both 17β-estradiol and a congener. Cell proliferation was determined by measuring BrdU incorporation, and cell apoptosis was measured by caspase-9 activity. No PBDE congener had an effect on basal cell proliferation, but they all significantly decreased basal caspase-9 activity. An additive anti-apoptotic activity and ability to induce cell proliferation was observed in the presence of 17β-estradiol.

Resistin is a survival factor for porcine ovarian follicular cells

Previously, we demonstrated the expression of resistin in the porcine ovary, the regulation of its expression and its direct effect on ovarian steroidogenesis. The objective of this study was to examine the effect of resistin on cell proliferation and apoptosis in a co-culture model of porcine granulosa and theca cells. First, we analysed the effect of resistin at 1 and 10  ng/ml alone or in combination with FSH- and IGF1 on ovarian cell proliferation with an alamarBlue assay and protein expression of cyclins A and B using western blot. Next, the mRNA and protein expression of selected pro-apoptotic and pro-survival regulators of cell apoptosis, caspase-9, -8 and -3 activity and DNA fragmentation using real time PCR, western blot, fluorescent assay and an ELISA kit, respectively, were analysed after resistin treatment. Furthermore, we determined the effect of resistin on the protein expression of ERK1/2, Stat and Akt kinase. Using specific inhibitors of these kinases, we also checked caspase-3 activity and protein expression. We found that resistin, at both doses, has no effect on cell proliferation. The results showed that resistin decreased pro-apoptotic genes, which was confirmed on protein expression of selected factors. We demonstrate an inhibitory effect of resistin on caspase activity and DNA fragmentation. Finally, resistin stimulated phosphorylation of the ERK1/2, Stat and Akt and kinases inhibitors reversed resistin action on caspase-3 activity and protein expression to control. All of these results showed that resistin has an inhibitory effect on porcine ovarian cell apoptosis by activation of the MAPK/ERK, JAK/Stat and Akt/PI3 kinase signalling pathways.

Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells

Histone deacetylases (HDACs) are often overexpressed in cancer cells, leading to altered expression and activity of numerous proteins involved in carcinogenesis. Recent evidence suggests that expression of class I HDACs is increased in ovarian carcinomas and plays a significant role in carcinogenesis and resistance to chemotherapeutic agents. Two compounds, valproic acid (VPA) and levetiracetam (LEV), exhibit HDAC inhibitor (HDACI) activity in various cell types, but data concerning their activity in ovarian cancer are lacking. Here we compared the effects of VPA and LEV as HDACIs, using a human ovarian cancer cell line, OVCAR-3. Cells were cultured with VPA or LEV at concentrations between 1 and 10 mM for 1-24h. HDAC activity was determined by fluorometric assay and confirmed by western blotting. Expression of HDAC genes was determined by real-time PCR and HDAC proteins expression was evaluated by western blotting. Additionally, we used high-performance liquid chromatography to determine whether OVCAR-3 cells can metabolize LEV to its major metabolite, 2-pyrrolidinone-n-butyric acid (PBA), which might exert HDACI activity. LEV, however, had no apparent effect on HDAC activity, or gene and protein expression. The OVCAR-3 cell line was able to metabolize LEV to PBA, but the effect was small. Our observations suggest that VPA should be considered as a possible adjunctive drug in ovarian cancer treatment.